U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H17F2N3O2
Molecular Weight 345.3433
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-265246

SMILES

CCCCOC1=C2C=NNC2=NC=C1C(=O)C3=C(F)C=C(C)C=C3F

InChI

InChIKey=SCFMWQIQBVZOQR-UHFFFAOYSA-N
InChI=1S/C18H17F2N3O2/c1-3-4-5-25-17-11(8-21-18-12(17)9-22-23-18)16(24)15-13(19)6-10(2)7-14(15)20/h6-9H,3-5H2,1-2H3,(H,21,22,23)

HIDE SMILES / InChI

Molecular Formula C18H17F2N3O2
Molecular Weight 345.3433
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21216932

BMS 265246 is a potent inhibitor of cyclin dependent kinase 1 and 2. It was under investigation with BristolMyers Squibb in the USA with potential in the treatment of cancer, however, BristolMyers Squibb no longer lists this product on its research and development pipelines which suggests that development of the programme has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.006 µM [IC50]
0.009 µM [IC50]
0.23 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues.
2003 Jul 21
A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators.
2011 Feb
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
Kinase reactions consisted of 100 ng of baculovirus expressed GST-CDK1/cyclin B1 complex, 1 µg histone H1 (Boehringer Mannheim, Indianapolis, IN), 0.2 µCi 33P γ-ATP, 25 µM ATP in 50 µL of kinase buffer (50 mM Tris, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 0.5 mM DTT). Reactions were incubated for 45 min at 30 °C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15%. TCA precipitates were collected onto GF/C unifilter plates (Packard Instrument Co., Meriden, CT) using a Filtermate universal harvester (Packard Instrument Co.), and the filters were quantitated using a TopCount 96 well liquid scintillation counter (Packard Instrument Co.). Dose response curves were generated to determine the concentration required to inhibit 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in DMSO and evaluated at six concentrations, each in triplicate. The final concentration of DMSO in the assay equaled 2%.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:27:37 GMT 2023
Edited
by admin
on Sat Dec 16 09:27:37 GMT 2023
Record UNII
4GF4A623RF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-265246
Common Name English
METHANONE, (4-BUTOXY-1H-PYRAZOLO(3,4-B)PYRIDIN-5-YL)(2,6-DIFLUORO-4-METHYLPHENYL)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID00206969
Created by admin on Sat Dec 16 09:27:37 GMT 2023 , Edited by admin on Sat Dec 16 09:27:37 GMT 2023
PRIMARY
CAS
582315-72-8
Created by admin on Sat Dec 16 09:27:37 GMT 2023 , Edited by admin on Sat Dec 16 09:27:37 GMT 2023
PRIMARY
FDA UNII
4GF4A623RF
Created by admin on Sat Dec 16 09:27:37 GMT 2023 , Edited by admin on Sat Dec 16 09:27:37 GMT 2023
PRIMARY
PUBCHEM
5329775
Created by admin on Sat Dec 16 09:27:37 GMT 2023 , Edited by admin on Sat Dec 16 09:27:37 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY